RxDoctor Payments Data

Myriame Vastey, MD

Family Medicine · Gainesville, FLNPI 1649245804

Payments from drug & device makers

$272in general payments, 2019–2025

Across 15 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$79
  • Gilead$50
  • Novo Nordisk$50
  • Lilly USA, LLC$28
  • Pfizer$27
  • Inogen, Inc.$14
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$25794%
  • Education$156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK5$79
Gilead2$50
Novo Nordisk1$50
Lilly USA, LLC2$28
Pfizer2$27
Inogen, Inc.1$14
AbbVie1$12
Boehringer Ingelheim1$12

How this compares

$272 in reported general payments places this provider in the 40th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$142,576
Medicare patients
477
Services billed
2,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$105,657
JardianceEmpagliflozin60$74,213
EliquisApixaban29$38,880
TrulicityDulaglutide23$28,000
JanuviaSitagliptin Phosphate17$25,685
XareltoRivaroxaban18$23,522
LinzessLinaclotide15$17,360
MounjaroTirzepatide12$12,419
InvokanaCanagliflozin11$5,282
Breo ElliptaFluticasone/Vilanterol13$5,015
Pregabalin44$4,058
Atorvastatin Calcium399$3,759
Omeprazole200$3,497
Rosuvastatin Calcium258$3,386
Gabapentin133$3,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$50$105,657105 claims
Boehringer IngelheimJardiance$12$74,21360 claims
Lilly USA, LLCTrulicity, Mounjaro$28$40,42035 claims
PfizerEliquis$27$38,88029 claims
AbbVieLinzess, Synthroid$12$18,55542 claims
GSKBreo Ellipta$79$5,01513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →